Glenmark Prescribed drugs Ltd. swung to revenue within the quarter ended March, however missed analysts’ estimates.
The corporate posted a revenue of Rs 4.7 crore within the fourth quarter as in comparison with Rs 1,218-crore loss within the year-ago interval, in keeping with an trade submitting on Friday. Analysts tracked by Bloomberg had estimated a internet revenue of Rs 344 crore.
Glenmark This fall Highlights (Consolidated, YoY)
-
Income up 6.3% at Rs 3,256 crore versus Rs 3,063 crore. (Bloomberg estimate: Rs 3,365 crore)
-
Ebitda up 11% at Rs 561 crore versus Rs 504 crore. (Bloomberg estimate: Rs 3,365 crore)
-
Margin at 17.2% versus 16.5%. (Bloomberg estimate: Rs 3,365 crore).
-
Web revenue at Rs 4.7 crore versus a lack of Rs 1,218 crore. (Bloomberg estimate: Rs 344 crore)
Dividend
The corporate declared a dividend of Rs 2.5 apiece with a face worth of Rs 2 every for fiscal 2025. It’s topic to approval on the annual basic assembly. The dividend will likely be paid inside 30 days of the AGM.
The agency might disburse as much as Rs 70.5 crore in dividend payouts to their shareholders. Retail Buyers could also be paid as much as Rs 8.6 crore in dividend payouts.
Shares of Glenmark Pharma closed 0.66% decrease at Rs 1,420.2 apiece on the NSE, in comparison with a 0.99% rise within the benchmark Nifty.
. Learn extra on Earnings by Newsstate24 Revenue.
